SESN3

Summary

SESN3 (sestrin 3, HGNC:23060) is a protein-coding gene on chromosome 11q21, encoding Sestrin-3 (P58005). May function as an intracellular leucine sensor that negatively regulates the TORC1 signaling pathway.

This gene encodes a member of the sestrin family of stress-induced proteins. The encoded protein reduces the levels of intracellular reactive oxygen species induced by activated Ras downstream of RAC-alpha serine/threonine-protein kinase (Akt) and FoxO transcription factor. The protein is required for normal regulation of blood glucose, insulin resistance and plays a role in lipid storage in obesity. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 143686 — RefSeq curated summary.

At a glance

• GWAS associations: 13
• Clinical variants (ClinVar): 48 total
• MANE Select transcript: NM_144665

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23060
Approved symbol	SESN3
Name	sestrin 3
Location	11q21
Locus type	gene with protein product
Status	Approved
Aliases	SEST3, MGC29667
Ensembl gene	ENSG00000149212
Ensembl biotype	protein_coding
OMIM	607768
Entrez	143686

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000278499, ENST00000416495, ENST00000536441, ENST00000537480, ENST00000542176, ENST00000634898

RefSeq mRNA: 2 — MANE Select: NM_144665 NM_001271594, NM_144665

CCDS: CCDS60938, CCDS8303

Canonical transcript exons

ENST00000536441 — 10 exons

Exon	Start	End
ENSE00000989389	95189779	95189961
ENSE00000989390	95185256	95185492
ENSE00000989391	95184420	95184594
ENSE00000989392	95178710	95178828
ENSE00000989393	95177719	95177909
ENSE00000989394	95175498	95175642
ENSE00002209055	95230783	95231202
ENSE00002211016	95165513	95173341
ENSE00003568554	95191404	95191601
ENSE00003610301	95193457	95193522

Expression profiles

Bgee: expression breadth ubiquitous, 263 present calls, max score 99.35.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.4662 / max 664.7692, expressed in 1447 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
121863	14.5658	1427
121862	0.9155	387
121864	0.6926	306
121866	0.1130	26
121865	0.0703	22
121867	0.0548	10
121861	0.0542	17

Top tissues by expression

265 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	99.35	gold quality
lateral nuclear group of thalamus	UBERON:0002736	97.77	gold quality
pigmented layer of retina	UBERON:0001782	97.60	gold quality
retina	UBERON:0000966	97.57	gold quality
medial globus pallidus	UBERON:0002477	97.42	gold quality
globus pallidus	UBERON:0001875	96.76	gold quality
trigeminal ganglion	UBERON:0001675	96.59	gold quality
mucosa of paranasal sinus	UBERON:0005030	96.23	gold quality
dorsal plus ventral thalamus	UBERON:0001897	95.74	gold quality
epithelium of nasopharynx	UBERON:0001951	95.15	gold quality
nasopharynx	UBERON:0001728	95.13	gold quality
calcaneal tendon	UBERON:0003701	94.77	gold quality
dorsal root ganglion	UBERON:0000044	94.68	gold quality
lateral globus pallidus	UBERON:0002476	94.64	gold quality
subthalamic nucleus	UBERON:0001906	94.63	gold quality
tendon	UBERON:0000043	94.52	gold quality
tibia	UBERON:0000979	94.26	gold quality
medulla oblongata	UBERON:0001896	94.21	gold quality
tendon of biceps brachii	UBERON:0008188	94.21	gold quality
superior vestibular nucleus	UBERON:0007227	94.13	gold quality
ventral tegmental area	UBERON:0002691	94.05	gold quality
germinal epithelium of ovary	UBERON:0001304	94.03	gold quality
oviduct epithelium	UBERON:0004804	94.00	gold quality
upper arm skin	UBERON:0004263	93.95	gold quality
ventricular zone	UBERON:0003053	93.83	gold quality
skin of hip	UBERON:0001554	93.70	gold quality
mammary duct	UBERON:0001765	93.58	gold quality
superficial temporal artery	UBERON:0001614	93.50	gold quality
epithelium of mammary gland	UBERON:0003244	93.50	gold quality
right testis	UBERON:0004534	93.14	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-CURD-97	no	2394.37
E-CURD-95	no	285.48
E-GEOD-124858	no	142.31
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FOXO1, FOXO3, HSF1

miRNA regulators (miRDB)

364 targeting SESN3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-1193	100.00	65.93	529
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-433-3P	99.98	69.37	1203

Literature-anchored findings (GeneRIF, showing 19)

• FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor (PMID:20412774)
• HSF1/SESN3/reactive oxygen species/p21(Cip1/WAF1)-mediated deceleration of cell growth may contribute to cell defense systems protecting the organism from excessive proliferation of cells that overexpress activated Ras oncoproteins. (PMID:23388456)
• Sestrin 3 is upregulated in T2D and could influence skeletal muscle differentiation without altering glucose and lipid metabolism. (PMID:24129397)
• findings suggest the existence of a novel mechanism for the generation of antileukemic responses in CML cells, involving upregulation of SESN3 expression. (PMID:24260131)
• Suggest that inhibitory effect of ethanol on Sesn3 may play an important role in the development of ethanol-induced fatty liver. (PMID:24833709)
• SESN3 positively regulates the gene network module in macrophages, microglia and neurons. (PMID:25615886)
• study revealed high confidence set of BMos (integrated with DNase I hypersensitivity sites) in the upstream regulatory regions of SESN3 that could be bound by transcription factors from multiple families including FOXOs, SMADs, SOXs, TCFs and HNF4A. TF-TF network analysis established hubs of interaction that include SMAD3, TCF3, SMAD2, HDAC2, SOX2, TAL1 and TCF12 as well as the likely protein complexes formed between them (PMID:27466818)
• Treatment with cucurbitacin B to sestrin-3 siRNA treated EGFR-mutant cells further amplified the decrease in cell-viability and caused more sustained G2-phase cell cycle arrest, suggesting that these effects are mediated partly through sestrin-3. (PMID:27881463)
• in FOXO3-death-resistant cells no point mutations in the TP53-DBD were found-in these cells FOXO3-TP53 complexes are formed and FOXO3-binding to the BIM-promoter, but not the induction of the detoxifying protein SESN3, were prevented, which in turn increased chemo-protection in this type of high-stage-derived neuroblastoma (NB)cells (PMID:28869600)
• Results suggest that Sesn3 is a target gene for rno-miR-155. Moreover, the rno-miR-155 antagonist may induce the expression of Sesn3, and then indirectly decrease the damage of oxidative stress to protect the brain from epileptogenesis-associated impairments. (PMID:29191771)
• It is possible that the over expression of the SESN3 gene, known to suppress oxidative damage, may have contributed to the attenuation of fatigue in Puerto Rican Men during Radiotherapy for Prostate Cancer (PMID:29220067)
• The expression of SESN3 and (TSC2 and FOXO1) was identified in Lewy bodies from brainstem. (PMID:29966750)
• identified new interactions between miR-200 and the oxidative stress response SESN proteins that affect anoikis resistance in human endometrial cancer cells. (PMID:31073887)
• Circulating Sestrin Levels Are Increased in Hypertension Patients. (PMID:32626541)
• Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease. (PMID:33082554)
• Oncogenic role of early growth response-1 in liver cancer through the regulation of the microRNA-675/sestrin 3 and the Wnt/beta-catenin signaling pathway. (PMID:34409922)
• The functions and roles of sestrins in regulating human diseases. (PMID:34979914)
• Genetic variations in a Sestrin2/Sestrin3/mTOR Axis and development of new-onset diabetes after kidney transplantation. (PMID:37918578)
• Inhibition of nucleo-cytoplasmic proteasome translocation by the aromatic amino acids or silencing Sestrin3-their sensing mediator-is tumor suppressive. (PMID:39266717)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	sesn3	ENSDARG00000015822
mus_musculus	Sesn3	ENSMUSG00000032009
rattus_norvegicus	Sesn3	ENSRNOG00000008173
drosophila_melanogaster	Sesn	FBGN0034897
caenorhabditis_elegans	sesn-1	WBGENE00022279

Paralogs (2): SESN1 (ENSG00000080546), SESN2 (ENSG00000130766)

Protein

Protein identifiers

Sestrin-3 — P58005 (reviewed: P58005)

All UniProt accessions (3): P58005, A0A0U1RR17, F5H1K7

UniProt curated annotations — full annotation on UniProt →

Function. May function as an intracellular leucine sensor that negatively regulates the TORC1 signaling pathway. May also regulate the insulin-receptor signaling pathway through activation of TORC2. This metabolic regulator may also play a role in protection against oxidative and genotoxic stresses. May prevent the accumulation of reactive oxygen species (ROS) through the alkylhydroperoxide reductase activity born by the N-terminal domain of the protein.

Subunit / interactions. Interacts with the GATOR2 complex which is composed of MIOS, SEC13, SEH1L, WDR24 and WDR59; the interaction is not regulated by leucine. Interacts with RRAGA, RRAGB, RRAGC and RRAGD; may function as a guanine nucleotide dissociation inhibitor for RRAGs and regulate them. Interacts with the TORC2 complex; through RICTOR.

Subcellular location. Cytoplasm.

Tissue specificity. Widely expressed.

Domain organisation. The N-terminal domain may have an alkylhydroperoxide reductase activity. The C-terminal domain mediates interaction with GATOR2 through which it regulates TORC1 signaling.

Similarity. Belongs to the sestrin family.

Isoforms (3)

UniProt ID	Names	Canonical?
P58005-1	1	yes
P58005-3	3
P58005-4	2

RefSeq proteins (2): NP_001258523, NP_653266* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006730	Sestrin	Family
IPR029032	AhpD-like	Homologous_superfamily

Pfam: PF04636

Catalyzed reactions (Rhea), 1 shown:

• a hydroperoxide + L-cysteinyl-[protein] = S-hydroxy-L-cysteinyl-[protein] + an alcohol (RHEA:67124)

UniProt features (13 total): splice variant 4, binding site 3, region of interest 2, sequence variant 2, chain 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P58005-F1	82.23	0.61

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 121 (cysteine sulfenic acid (-soh) intermediate)

Ligand- & substrate-binding residues (3): 386–389; 398; 463

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-5628897	TP53 Regulates Metabolic Genes
R-HSA-212436	Generic Transcription Pathway
R-HSA-3700989	Transcriptional Regulation by TP53
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)

MSigDB gene sets: 473 (showing top): GCM_MAP4K4, RRAGTTGT_UNKNOWN, SHEPARD_BMYB_MORPHOLINO_UP, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_REGULATION_OF_AUTOPHAGY, YAATNRNNNYNATT_UNKNOWN, WWTAAGGC_UNKNOWN, GOBP_RESPONSE_TO_ACID_CHEMICAL, LFA1_Q6, GOZGIT_ESR1_TARGETS_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, FOXO4_01, FOXO1_01, GOBP_CELLULAR_RESPONSE_TO_ACID_CHEMICAL, AAAYRNCTG_UNKNOWN

GO Biological Process (13): positive regulation of macroautophagy (GO:0016239), response to insulin (GO:0032868), cellular response to amino acid starvation (GO:0034198), TORC2 signaling (GO:0038203), cellular response to glucose starvation (GO:0042149), glucose homeostasis (GO:0042593), regulation of insulin receptor signaling pathway (GO:0046626), regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0051896), cellular response to L-leucine (GO:0071233), regulation of response to reactive oxygen species (GO:1901031), negative regulation of TORC1 signaling (GO:1904262), cellular response to leucine starvation (GO:1990253), cellular response to amino acid stimulus (GO:0071230)

GO Molecular Function (4): oxidoreductase activity, acting on peroxide as acceptor (GO:0016684), L-leucine binding (GO:0070728), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (4): nucleus (GO:0005634), cytoplasm (GO:0005737), TORC2 complex (GO:0031932), GATOR2 complex (GO:0061700)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Transcriptional Regulation by TP53	1
RNA Polymerase II Transcription	1
Generic Transcription Pathway	1
Gene expression (Transcription)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular response to starvation	2
positive regulation of autophagy	1
macroautophagy	1
regulation of macroautophagy	1
response to peptide hormone	1
response to amino acid starvation	1
TOR signaling	1
carbohydrate homeostasis	1
insulin receptor signaling pathway	1
regulation of signal transduction	1
phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
regulation of intracellular signal transduction	1
response to L-leucine	1
cellular response to amino acid stimulus	1
cellular response to nitrogen compound	1
cellular response to oxygen-containing compound	1
response to reactive oxygen species	1
regulation of response to oxidative stress	1
negative regulation of TOR signaling	1
TORC1 signaling	1
regulation of TORC1 signaling	1
cellular response to amino acid starvation	1
response to amino acid	1
cellular response to acid chemical	1
oxidoreductase activity	1
amino acid binding	1
carboxylic acid binding	1
cation binding	1
binding	1
catalytic activity	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1
TOR complex	1
protein-containing complex	1
Seh1-associated complex	1

Protein interactions and networks

STRING

582 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SESN3	CACNA2D2	Q9NY47	844
SESN3	RICTOR	Q6R327	626
SESN3	TP53	P04637	609
SESN3	WDR24	Q96S15	580
SESN3	WDR59	Q6PJI9	523
SESN3	TP53I3	Q53FA7	498
SESN3	MIOS	Q9NXC5	490
SESN3	FOXO1	Q12778	487
SESN3	NPRL3	Q12980	478
SESN3	TSC2	P49815	460
SESN3	MTOR	P42345	454
SESN3	NPRL2	Q8WTW4	451
SESN3	FOXO3	O43524	447
SESN3	PRDX1	P35703	444
SESN3	RHEB	Q15382	433

IntAct

9 interactions, top by confidence:

A	B	Type	Score
WDR24	SESN2	psi-mi:“MI:0914”(association)	0.890
WDR24	SEC13	psi-mi:“MI:0914”(association)	0.730
WDR24	SESN3	psi-mi:“MI:0915”(physical association)	0.620
SESN3	NPRL3	psi-mi:“MI:0914”(association)	0.350
SESN3	MYCBP2	psi-mi:“MI:0914”(association)	0.350
DYRK1A	TEX13D	psi-mi:“MI:0914”(association)	0.350
DSCR9	SESN3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (15): SESN3 (Affinity Capture-MS), ZFP1 (Affinity Capture-MS), MYCBP2 (Affinity Capture-MS), ZFP1 (Affinity Capture-MS), MYCBP2 (Affinity Capture-MS), WDR59 (Reconstituted Complex), MIOS (Reconstituted Complex), WDR24 (Reconstituted Complex), NPRL3 (Reconstituted Complex), MYCBP2 (Affinity Capture-MS), ZFP1 (Affinity Capture-MS), SESN3 (Affinity Capture-MS), SESN3 (Two-hybrid), SESN3 (Affinity Capture-MS), SESN3 (Affinity Capture-RNA)

ESM2 similar proteins: A0JM23, A4IGD2, A5PKL6, A6NHR9, A6QQZ0, D3ZAT9, F1QWA8, O35099, O88741, O94952, P0CI65, P58005, Q29RL0, Q2TBQ7, Q3U213, Q3UMF9, Q4R6P7, Q4R6Y8, Q5E9N5, Q5F204, Q5HYI7, Q5I0G3, Q5IH14, Q5R5S1, Q5R9R1, Q5RL51, Q5TGI0, Q60649, Q6AZT7, Q6DDI6, Q6DDT5, Q6DEY8, Q6NXY1, Q6YXW6, Q7TNH6, Q7Z494, Q8NBP0, Q8NEC7, Q8TB36, Q94E75

Diamond homologs: P58003, P58004, P58005, P58006, P58043, Q4R6P7, Q54WU6, Q58CN8, Q5RCB4, Q9CYP7, Q9W1K5, Q9Y6P5

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SESN3	“down-regulates activity”	GATOR2	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

48 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	37
Likely benign	0
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1563 predictions. Top by Δscore:

Variant	Effect	Δscore
11:95173204:T:C	donor_gain	1.0000
11:95173240:T:TA	donor_gain	1.0000
11:95173255:T:TA	donor_gain	1.0000
11:95173340:ACCTA:A	acceptor_loss	1.0000
11:95173343:T:C	acceptor_loss	1.0000
11:95175491:CACGT:C	donor_loss	1.0000
11:95175492:ACGTA:A	donor_loss	1.0000
11:95175495:TAC:T	donor_loss	1.0000
11:95175496:A:AC	donor_gain	1.0000
11:95175496:ACTTT:A	donor_loss	1.0000
11:95175497:C:CA	donor_gain	1.0000
11:95175497:CT:C	donor_gain	1.0000
11:95175497:CTTT:C	donor_gain	1.0000
11:95175497:CTTTT:C	donor_gain	1.0000
11:95175638:CATAC:C	acceptor_gain	1.0000
11:95175641:ACCT:A	acceptor_loss	1.0000
11:95175643:C:T	acceptor_loss	1.0000
11:95175644:T:A	acceptor_loss	1.0000
11:95177714:CATA:C	donor_loss	1.0000
11:95177715:ATAC:A	donor_loss	1.0000
11:95177716:TACCT:T	donor_loss	1.0000
11:95177717:A:C	donor_loss	1.0000
11:95177718:CC:C	donor_loss	1.0000
11:95177782:T:TA	donor_gain	1.0000
11:95177905:TAGTC:T	acceptor_gain	1.0000
11:95177906:AGTC:A	acceptor_gain	1.0000
11:95177907:GTC:G	acceptor_gain	1.0000
11:95177908:TC:T	acceptor_gain	1.0000
11:95177908:TCCTA:T	acceptor_loss	1.0000
11:95177909:CC:C	acceptor_gain	1.0000

AlphaMissense

3265 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:95175588:C:A	K434N	1.000
11:95175588:C:G	K434N	1.000
11:95177725:C:T	G414E	1.000
11:95177898:C:A	W356C	1.000
11:95177898:C:G	W356C	1.000
11:95177900:A:G	W356R	1.000
11:95177900:A:T	W356R	1.000
11:95185465:A:G	W185R	1.000
11:95185465:A:T	W185R	1.000
11:95189805:A:G	W167R	1.000
11:95189805:A:T	W167R	1.000
11:95191423:C:A	R108M	1.000
11:95173295:A:G	L480P	0.999
11:95173310:C:G	R475P	0.999
11:95173328:A:G	L469P	0.999
11:95175498:T:A	K464N	0.999
11:95175498:T:G	K464N	0.999
11:95175514:A:G	F459S	0.999
11:95175524:A:G	W456R	0.999
11:95175524:A:T	W456R	0.999
11:95175559:G:T	P444H	0.999
11:95175564:G:C	C442W	0.999
11:95175576:C:A	K438N	0.999
11:95175576:C:G	K438N	0.999
11:95175590:T:C	K434E	0.999
11:95175626:A:G	Y422H	0.999
11:95177725:C:A	G414V	0.999
11:95177726:C:G	G414R	0.999
11:95177726:C:T	G414R	0.999
11:95177887:C:T	G360E	0.999

dbSNP variants (sampled 300 via entrez): RS1000054643 (11:95188979 A>G), RS1000092960 (11:95208295 C>G,T), RS1000118201 (11:95186320 TAAAACAAAAC>T,TAAAAC,TAAAACAAAACAAAAC), RS1000146597 (11:95234281 C>T), RS1000164822 (11:95207592 T>C), RS1000193686 (11:95188557 C>T), RS1000266162 (11:95193989 T>A,C), RS1000286092 (11:95222887 T>C), RS1000350296 (11:95196075 A>G), RS1000361925 (11:95204608 A>G,T), RS1000425337 (11:95200938 T>G), RS1000455250 (11:95204269 T>C), RS1000463211 (11:95178214 A>G), RS1000471397 (11:95181257 G>A,C), RS1000567694 (11:95208624 CA>C)

Disease associations

OMIM: gene MIM:607768 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST005038_133	Allergic disease (asthma, hay fever or eczema)	2.000000e-11
GCST005183_2	Common carotid intima-media thickness	1.000000e-06
GCST005184_1	Common carotid intima-media thickness in HIV infection	5.000000e-06
GCST007094_180	Diastolic blood pressure	3.000000e-11
GCST007098_73	Diastolic blood pressure	5.000000e-06
GCST007098_74	Diastolic blood pressure	7.000000e-06
GCST007576_199	Chronotype	8.000000e-09
GCST009615_13	Triglyceride levels x loop diuretics use interaction	1.000000e-06
GCST010796_5346	Electrocardiogram morphology (amplitude at temporal datapoints)	5.000000e-09
GCST010796_5347	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-08
GCST010796_5348	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-08
GCST010796_5349	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-08
GCST90011899_59	Aspartate aminotransferase levels	1.000000e-08

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0006336	diastolic blood pressure
EFO:0008328	chronotype measurement
EFO:0004530	triglyceride measurement
EFO:0004327	electrocardiography
EFO:0004736	aspartate aminotransferase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

65 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	increases expression	8
Valproic Acid	affects cotreatment, decreases expression, increases expression	4
Acetaminophen	affects expression, decreases expression, increases expression	3
Air Pollutants	decreases expression, increases abundance, increases expression	3
Estradiol	affects cotreatment, decreases expression	3
Tetrachlorodibenzodioxin	decreases expression, affects expression	3
Cyclosporine	decreases expression	3
OTX015	increases expression	2
methylmercuric chloride	increases expression, decreases expression	2
bisphenol A	affects cotreatment, decreases methylation, increases expression	2
trichostatin A	affects expression, decreases expression	2
sodium arsenite	decreases expression, increases expression	2
scriptaid	affects expression, increases expression	2
Vorinostat	increases expression	2
Tobacco Smoke Pollution	decreases expression	2
Aflatoxin B1	decreases expression, decreases methylation, affects expression	2
Particulate Matter	increases expression, decreases expression, increases abundance	2
mivebresib	increases expression	1
geldanamycin	increases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
beta-lapachone	decreases expression	1
resorcinol	decreases expression	1
hydroquinone	decreases expression	1
lei gong teng	increases expression	1
epigallocatechin gallate	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluoro-n-nonanoic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.